Literature DB >> 3128415

An interaction between cytostatic and anticonvulsant drugs.

C Neef1, I de Voogd-van der Straaten.   

Abstract

A young woman with epilepsy had tonic-clonic seizures during antineoplastic therapy with adriamycin and cisplatin. During two courses of cytostatic drug administration peak and trough plasma levels of phenytoin, carbamazepine, and valproate sodium were measured. Lower plasma levels of carbamazepine and valproate sodium were observed after 2 days of antineoplastic therapy. Normal plasma levels of these drugs were found 2 to 3 days after the last cisplatin dose. Impaired absorption or accelerated elimination might explain these results. Phenytoin levels were reduced to 37% of the original values, although the drug was given intravenously. Changed Michaelis-Menten parameters suggest that cisplatin increases the metabolic rate of phenytoin. Another explanation for the decreased drug levels might be an increased volume of distribution. Calculation of this volume from peak and trough levels showed an increase of the volume of distribution during and after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128415     DOI: 10.1038/clpt.1988.45

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  [Relapsing reversible posterior leukoencephalopathy after chemotherapy with cisplatin and 5-fluorouracil].

Authors:  F Paul; O Aktas; F-J Dieste; P Kreitsch; H-P Vogel; F Zipp
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

2.  Doxorubicin pathways: pharmacodynamics and adverse effects.

Authors:  Caroline F Thorn; Connie Oshiro; Sharon Marsh; Tina Hernandez-Boussard; Howard McLeod; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-07       Impact factor: 2.089

Review 3.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 4.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 5.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 6.  Epilepsy in the elderly.

Authors:  Ilo E Leppik; Angela K Birnbaum
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

Review 7.  Optimal seizure management in brain tumor patients.

Authors:  Melanie S M van Breemen; Charles J Vecht
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

8.  Pharmacokinetic interaction on valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic patient.

Authors:  Hiroaki Ikeda; Teruo Murakami; Mikihisa Takano; Tsuguru Usui; Kenji Kihira
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

9.  Reduced Systemic and Brain Exposure with Inhibited Liver Metabolism of Carbamazepine After Its Long-Term Combination Treatment with Piperine for Epilepsy Control in Rats.

Authors:  Tianjing Ren; Min Xiao; Mengbi Yang; Jiajia Zhao; Yufeng Zhang; Mengyun Hu; Yan Cheng; Hong Xu; Chunbo Zhang; Xiaoyu Yan; Zhong Zuo
Journal:  AAPS J       Date:  2019-07-18       Impact factor: 4.009

Review 10.  Antineoplastic agents. Drug interactions of clinical significance.

Authors:  E van Meerten; J Verweij; J H Schellens
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.